ArchiveJune 2015

Alemtuzumab, here I come: Top line results of the Ocrelizumab in relapsing MS studies

This morning, Roche announced the headline results of their Ocrelizumab in relapsing MS program (OPERA I and II).   Here is their press release: Numerous posts on this blog have highlighted the potential of this humanized version of Rituximab (check the “BartsMS essential off-label DMT list” in the left upper corner), an established drug to treat people with B cell lymphoma...

Vitamin D in Optic Neuritis Trial fails

Salari M, Janghorbani M, Etemadifar M, Dehghani A, Razmjoo H, Naderian G.Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: Preliminary findings of a randomized, placebo-controlled trial.J Res Med Sci. 2015;20(4):372-8 BACKGROUND:There is accumulating evidence for a possible protective role of vitamin D in the development and disease course of...

The US experience of natalizumab – both very telling and very important to tell

CNS Drugs. 2015 Jun 26. [Epub ahead of print] Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH, Bonafede MM, Watson C. BACKGROUND: Multiple sclerosis (MS) registry data, primarily from Europe, suggest that treatment with natalizumab delays time to relapse compared with platform therapy...

Neurologists are too blue…. ABN 2015 guidlelines

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Scolding N et al. Pract Neurol doi:10.1136/practneurol-2015-001139 The Association of British Neurologists (ABN) revised prescribing guidelines for the treatment of relapsing-remitting MS (RRMS) have been published. The whole document can be read online ...

ClinicSpeak: destigmatizing the wheelchair

Help! We need ideas on how to destigmatize the wheelchair. #ClinicSpeak #MSBlog #MSResearch “MS is many diseases in one. Not only does it floor you when you are diagnosed with the disease, but in those with relapse-onset disease it gets you again when you enter the secondary progressive phase of the disease; the point you realise that you have a progressive disabling disease. And again when...

New prescribing guidelines for multiple sclerosis

Scolding N et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Pract Neurol 2015 The Association of British Neurologists (ABN) revised prescribing guidelines for the treatment of relapsing-remitting MS (RRMS) have been published. MS charities had the opportunity to comment on the revisions and...

Brain lymphatics are like buses wait fifty years and two papers come all in a short space of time

Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015 . pii: jem.20142290. [Epub ahead of print] The central nervous system (CNS) is considered an organ devoid of lymphatic vasculature. Yet, part of the cerebrospinal fluid (CSF) drains into the cervical lymph...

MS Frontiers 2015

This is the biennial Science meeting  on behalf of the MS Society in the UK. This is held at Heathrow Airport.  However, if you want to see what’s going on CLICK HERE Follow on twitter #MSfroniters                                           The Debate:   ...

MS Frontiers 2015

Are you coming to the MS Frontiers Meeting at Heathrow tomorrow? #MSBlog #MSResearch “The following is the programme for the biennial MS Frontiers meeting. One person in Barts-MS complained to me the programme lacks energy and is simply ‘the same-old’ people on the platform. This person wants ‘youth’ and ‘new ideas’. The primary purpose of this meeting is...

Translate

Categories

Recent Posts

Recent Comments

Archives